Paclitaxel-Eluting Stents vs Vascular Brachytherapy for In-Stent Restenosis Within Bare-Metal Stents

Abstract

ClinicalTrials.gov Identifier: NCT00287573.

Intracoronary Brachytherapy for Recurrent Drug-Eluting Stent Failure

“…In the RESCUE (Radiation for Eluting Stents in Coronary Failure) trial, the overall recurrence rate of DES-ISR with VBT was 12% at 1 year. The trial also showed that VBT is a safe strategy in these There is a "late catch-up" phenomenon consistently observed in VBT studies on long-term followup, leading to late lumen loss (18)(19)(20). Results of the present study are consistent with those of the existing literature (19,20).…”

“…The trial also showed that VBT is a safe strategy in these There is a "late catch-up" phenomenon consistently observed in VBT studies on long-term followup, leading to late lumen loss (18)(19)(20). Results of the present study are consistent with those of the existing literature (19,20). In the WRIST (Washington Radiation for In-stent Restenosis Trial) trial, angiographic restenosis and TVR were reduced at 6 months in patients treated with VBT.…”

Clinical predictors of stent thrombosis in the “real world” drug-eluting stent era

“…In this clinical cohort of consecutive patients who received DES from 2002 to 2006 and followed up for a minimum period of 10 months, we noted a cumulative ST incidence of 1.5%, similar to rates reported in meta-analysis of recent trials [1][2][3][4][5][6]. With the current widespread availability of DES, the scope in routine clinical practice of PCI has also been expanded to more complex and so called 'off-label' lesions.…”

Three-year follow-up after treatment of bare-metal stent restenosis with first-generation or second-generation drug-eluting stents

“…Several registries and randomized clinical trials have demonstrated superiority of first-generation DES over balloon angioplasty and vascular brachytherapy for the treatment of BMS restenosis [6][7][8][12][13][14][15][16][17][18]. Our results compare favorably with those reported in the DES arm of the TAXUS V ISR trial (396 patients with BMS ISR), which evaluated the use of a PES versus brachytherapy for the treatment of BMS restenosis.…”